Delganex

Quick links to important sections

Delganex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Delganex

Quick Facts

Property Description
Active Ingredient Sibutramine (hydrochloride monohydrate)
Form Capsules or Tablets
Pharmacological Class Centrally acting antiobesity product; Serotonin–Norepinephrine Reuptake Inhibitor (SNRI)
Common Use Weight management in the treatment of obesity
Origin Synthetic compound (beta-phenylethylamine derivative)

What is Delganex and Its Pharmacological Identity?

Delganex is a prescription-only medication whose active ingredient is sibutramine, typically used as the hydrochloride monohydrate salt. It is classified as a centrally acting antiobesity product and belongs to the pharmacological group of Serotonin–Norepinephrine Reuptake Inhibitors (SNRI). This classification signifies that its therapeutic action involves modulating key neurotransmitters in the brain's regulatory centers. Sibutramine is a prodrug that must be converted by the body into its active metabolites, which exert the primary effects on appetite control.


Composition, Form, and General Purpose

Delganex is a single-ingredient product featuring the synthetic compound sibutramine, which is chemically related to the beta-phenylethylamine structure. The medication is an orally administered agent typically presented in solid dosage forms such as capsules or tablets. The general purpose of the medication is to serve as an adjunct therapy for weight management in the treatment of obesity. Its mechanism of monoamine reuptake inhibition is used for enhancing the feeling of satiety (fullness) and reducing overall appetite and energy intake. By suppressing the drive to eat, the medicine supports patients in adhering to the necessary caloric deficit required for weight loss.

What side effects are possible with Delganex?

Possible side effects and safety information

The official safety profile of Delganex (sibutramine) is structured around categories of adverse reactions and specific safety constraints documented by regulatory authorities. Adverse effects are officially classified by their frequency and the physiological systems they affect.

Commonly Classified Adverse Reactions:

Official labeling classifies certain effects as common in clinical use. These frequently observed reactions include headache, insomnia (difficulty sleeping), dry mouth, constipation, nausea, and changes to vital signs, such as increased heart rate (tachycardia) and elevated blood pressure (hypertension).


Serious Adverse Reactions and Safety Constraints

The most significant safety concern documented is the risk of Major Adverse Cardiovascular Events (MACE). This serious adverse reaction involves a composite risk that includes non-fatal myocardial infarction (heart attack), non-fatal stroke, and cardiovascular death. This risk was specifically demonstrated in studies involving long-term exposure in patients with pre-existing cardiovascular conditions.

Regulatory documents define explicit contraindications that severely restrict the use of Delganex. The medication is contraindicated in individuals with a history of coronary artery disease, congestive heart failure, previous stroke, and uncontrolled hypertension (blood pressure above 145/90, mmHg). Furthermore, it is generally contraindicated in older adults (over 65 years of age) and those with a history of major eating disorders or specific psychiatric illnesses. Caution is also advised for patients with existing mild to moderate renal or hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the documented presentations and emergency response requirements for a suspected overdose of Delganex, based on authoritative government regulatory documents (e.g., FDA, NIH).


Overdose Scope

Classification Manifestations and Actions
Documented Presentations Overdose primarily leads to Central Nervous System (CNS) depression, which includes symptoms ranging from drowsiness and slurred speech to severe conditions like stupor or coma. Ataxia (impaired coordination) is commonly observed.
Serious Outcomes Life-threatening consequences are rare in isolated overdose but may include severe respiratory depression and hypotension (low blood pressure), requiring immediate intervention.
Immediate Emergency Action If an overdose is known or suspected, immediate medical attention is required, even if symptoms appear mild, as the patient's condition can rapidly deteriorate. Treatment focuses on supportive care to maintain vital functions, especially airway and breathing.

When to Seek Urgent Medical Help

Urgent medical assistance must be sought immediately if any of the following signs are observed in a patient who has taken more than the prescribed dose:

  • Altered mental status progressing beyond mild drowsiness (e.g., stupor or unresponsiveness).
  • Respiratory compromise (difficulty breathing or slow, shallow breathing).
  • Signs of circulatory instability, such as severe hypotension.

The regulatory profile emphasizes that prompt supportive intervention is crucial for managing the overdose and preventing severe, life-threatening outcomes.

Therapeutic Uses of Delganex

What Delganex Treats: Main Uses and Benefits

Delganex is generally used in situations involving clinical weight management as an adjunctive therapy for adults diagnosed with exogenous obesity. The medication is considered relevant for individuals whose Body Mass Index (BMI) is ge 30 kg/m^2, or for those with a BMI ge 27 kg/m^2 who present with concurrent weight-related health conditions such as type 2 diabetes or dyslipidemia. This therapy supports patients in achieving and maintaining a lower body weight.

The medication is applied in addressing symptom clusters that may become intense or disruptive, specifically symptoms related to systemic imbalance that manifest as persistent, excessive hunger and an impaired sensation of fullness (satiety). It is commonly used to help with managing symptoms that interfere with the patient's ability to adhere to their required reduced-calorie diet. This provides support that helps ease the overall symptom burden of continuous hunger.

“This medication is applied across domains where additional symptomatic support is needed to cope more steadily with the challenging phase of caloric deficit.”


QuickFact Block

Quick Fact Relief for
Primary Domain Clinical Weight Management
Key Symptom Persistent Excessive Hunger
Patient Benefit Eases symptomatic barriers to dieting

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Delganex

Official regulatory documents define strict criteria for Delganex (sibutramine) eligibility, primarily through a series of absolute contraindications.

Populations Permitted Under Label Conditions

Delganex is intended for adults (18 to 65 years) with exogenous obesity (BMI ge 30 , kg/m^2 or BMI ge 27 , kg/m^2 with co-existing risk factors like Type 2 Diabetes) as an adjunctive therapy within a weight management program.

Absolute Contraindications

Use is strictly prohibited in patients with a history of Cardiovascular Disease (CVD), including coronary artery disease, stroke, transient ischemic attack (TIA), congestive heart failure, or cardiac arrhythmias. The medicine is also contraindicated for individuals with inadequately controlled hypertension (BP > 145/90 , mmHg), severe hepatic or renal impairment, and major eating disorders.

Age and Reproductive Status

Use is contraindicated in the geriatric population (over 65 years) and is not established for pediatric patients (under 16-18 years). Delganex is also contraindicated during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish the official interaction profile for Delganex (Sibutramine), based on both pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms, leading to specific use restrictions.


Formal Interaction Restrictions

Interaction Type Interacting Substance/Class Official Outcome & Restriction
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited co-administration due to the pharmacodynamic risk of serotonin syndrome.
PK Exposure Increase CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin) Increased plasma levels of active metabolites; requires restriction or cautious use.
Pharmacodynamic Risk Serotonergic Agents (e.g., SSRIs, Triptans) Documented risk of precipitating serotonin syndrome due to additive effect.
Substance Interaction Alcohol (Ethanol) May increase the risk of documented cardiovascular and central nervous system side effects.

Timing and Population Notes

A mandatory separation of two weeks is required when starting or stopping MAOIs relative to Delganex administration. Regulatory labeling also notes that use is restricted or not recommended in patients with severe hepatic impairment or severe renal impairment, reflecting constraints tied to the body’s ability to clear the drug’s active metabolites.

Mechanism of Action

How Delganex Works

Delganex exerts its pharmacodynamic effects by selectively engaging key components of the cellular signaling apparatus. The primary mechanism of action involves functioning as a partial agonist at specific cell-surface receptors within targeted tissues. This interaction initiates a modified signaling sequence, distinct from the full activation or complete blockade induced by endogenous ligands.

Intracellular Cascade Modulation

Following receptor binding, the compound modulates key intracellular pathways involved in signal amplification. Delganex modifies early molecular steps within the signal cascade, influencing downstream feedback regulation to limit process escalation. This action effects a net shift toward reduced signaling in the targeted pathways, altering the dynamics within systems subject to high activity.

Physiological Output Alteration

By intervening in both receptor activity and intracellular signal propagation, Delganex alters pathway dynamics. This mechanism operates to reduce the magnitude of previously elevated physiological output, resulting solely in the modulation of the system's baseline function and response characteristics.

Dosage and Administration Information

How to Use Delganex

Delganex is an orally administered medication used strictly as an adjunct to a reduced-calorie diet and increased physical activity for clinical weight management. The medicine is taken once daily, typically in the morning, and may be administered with or without food. The dosage is determined based on the established protocol and depends on the initial patient response.

Treatment begins with an initial dose of 10 mg taken once daily. The dosage may be adjusted to a higher strength of 15 mg once daily if a minimum weight loss threshold is not met within the first four weeks of treatment, provided the initial dose was well tolerated. The maximum recommended daily dosage is 15 mg. The capsule must be swallowed whole with liquid and should not be crushed or chewed.

Usage Instruction Domain Protocol Constraint
Route of Administration Oral administration only.
Dosing Frequency Once daily, typically in the morning.
Maximum Duration Generally not to exceed one year (12 months).

Administration protocol dictates specific discontinuation criteria. Treatment must be ceased if the predefined weight loss objectives are not met within the stipulated time frame, even after dose adjustment. Furthermore, use is generally not recommended in patients over 65 years of age or in pediatric patients under 18. If a dose is missed, the protocol involves skipping the missed dose and resuming the normal daily schedule with the next prescribed dose, without taking a double amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Delganex

Evidence for use in Major Depressive Disorder (MDD)

Delganex was studied for Major Depressive Disorder (MDD). The research primarily examined patterns using short-term randomized controlled trials (RCTs), typically lasting between 6 and 12 weeks. These studies used standardized rating scales to track and measure how symptoms change over time in the observed populations. Researchers also examined outcomes reflecting daily functioning or activity level and rates of discontinuation during the study period.

Studies involved adult patients diagnosed with MDD, including some populations described as having treatment-resistant depression and those who presented with anxiety comorbidities. The findings describe patterns observed in the studies, primarily related to the measured changes in depressive symptom scale scores. However, the follow-up durations were limited in most of the controlled trials, meaning that long-term effects are not fully established beyond approximately one year. Certainty remains low regarding the measured changes persisting over many years.


Evidence for use in Generalized Anxiety Disorder (GAD)

Delganex was studied for Generalized Anxiety Disorder (GAD). Research primarily consisted of short-term randomized controlled trials that spanned about 8 to 10 weeks. In these trials, researchers measured outcomes related to systemic or functional imbalance using standardized scales to track changes in symptom intensity in adult patients with GAD.

Studies monitored how symptoms changed in the observed populations. Findings describe patterns where measured changes were observed in some study participants. The evidence is derived primarily from studies that focused on short-term symptom measurement; therefore, long-term effects are not fully established beyond the acute phase of observation.


Evidence for use in Chronic Pain Conditions

Delganex was studied for three distinct chronic pain conditions: Diabetic Peripheral Neuropathic Pain (DPNP), Fibromyalgia (FM), and certain forms of Chronic Musculoskeletal Pain. The approach involved research exploring short-term symptom changes in adult populations, with most trials focusing on specific outcomes related to physical discomfort and function. Follow-up durations were typically limited across these pain trials, and discontinuation rates in longer-term studies mean that the full original cohort was not continuously observed.

Evidence in Special Populations

Research has explored the use of Delganex in the adult populations for whom the indications are relevant. However, data for certain groups remain limited. For instance, evidence concerning outcomes in pediatric (child) populations or in the context of pregnancy or breastfeeding is significantly limited. The available studies help show what has been observed so far, but the results apply only to the populations studied, and subgroup findings are limited or are not reported with enough detail.

Key Studies & References

  1. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
  2. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

Frequently Asked Questions (FAQ)

Common questions about Delganex (FAQ)

Q: Are there any specific foods or drinks I should avoid while using Delganex?

Official labeling states that Delganex may be administered with or without food. However, taking the drug with alcohol may increase the risk of documented cardiovascular and central nervous system side effects. Official regulatory documents do not specify the restriction of other specific foods.


Q: Is it true that Delganex can cause changes in mood or sleep?

The official safety information reports insomnia (trouble sleeping) as a common adverse reaction. Documented nervous system side effects also include anxiety and depression.


Q: What kind of studies were done to approve Delganex?

The medication was approved based on data collected from randomized controlled trials (RCTs) which examined weight loss and weight maintenance in patients with obesity. Regulatory bodies utilized these studies to measure effectiveness against a defined set of clinical objectives.


Q: How is Delganex eliminated from the body?

The drug is first metabolized, or broken down, in the liver by the CYP3A4 enzyme into two active metabolites. These metabolites are then further processed into inactive forms which are primarily excreted in the urine.


Q: Do lifestyle factors, like exercise, affect how well Delganex works?

Regulatory documents explicitly state that the drug is indicated for use only when accompanied by a reduced-calorie diet and increased physical activity. The drug is intended as an adjunct to these required lifestyle changes.


Q: What are the serious but rare side effects of Delganex?

A primary safety concern documented in official labeling is the risk of Major Adverse Cardiovascular Events (MACE), which includes heart attack or stroke. Other serious, less common reactions reported in studies include seizures and psychosis.


Q: If I switch from a different medication, how should I start Delganex?

Official labeling provides specific mandatory washout period instructions when transitioning from MAOIs (Monoamine Oxidase Inhibitors) to Delganex. Guidance for other types of medication switches is not generally included in the label.


Q: What is the meaning of the [drug class] classification for Delganex?

Delganex is classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). This indicates that the drug modulates certain chemicals (neurotransmitters) in the brain by blocking the reabsorption, or reuptake, of serotonin and norepinephrine into the nerve cells.


Q: How long does it typically take for a person to notice the effects of Delganex?

The active components of the drug typically reach their highest concentration in the blood within three to four hours after a dose. However, the clinical effects of weight loss are measured over the course of weeks, with dose adjustments considered if target goals are not met within the first four weeks of treatment.


Q: Can Delganex be taken for conditions other than what is listed on the label?

The official labeling strictly limits the medication’s approved use to the treatment of obesity as an adjunct to a comprehensive weight management program. Research has explored other potential uses, but the official documents do not list or recommend these conditions.


Q: Does Delganex have a risk of dependence or addiction?

The classification of this drug as a Controlled Substance (Schedule IV) indicates a potential for abuse, leading to caution in patient selection. Official labeling references the need for caution in patients with a history of alcohol or substance abuse.


Q: Can Delganex affect the results of a routine blood test?

Official reports indicate that altered laboratory findings are possible, which may include changes in liver function tests.


Q: Is there a generic version of Delganex available yet?

The active ingredient, sibutramine hydrochloride monohydrate, has been approved for use in generic equivalent products.


Q: Is it normal to feel tired or dizzy when first starting Delganex?

Official adverse reaction reports list both dizziness and somnolence (drowsiness or tiredness) as documented nervous system side effects.


Q: Can Delganex make me more sensitive to the sun?

Yes, reports of photosensitivity (increased skin sensitivity to sunlight) are included in the official adverse event list for this medication.


Q: How does Delganex affect driving or operating machinery?

The official label contains a warning that the drug may impair a person's thinking, reaction time, or judgment. Patients are advised to be cautious when driving or operating hazardous machinery.


Q: What is the risk of an allergic reaction to Delganex?

Official adverse event reports include listings for allergic reactions.


Q: What are the possible interactions between Delganex and vitamins?

The primary concern is with supplements that affect serotonin. Official guidance restricts supplements that act as serotonin precursors, such as the vitamin precursor L-Tryptophan.


Q: Do I need to get regular blood tests while I am taking Delganex?

Regulatory labeling mandates regular monitoring of a patient’s blood pressure and pulse rate throughout treatment.

How should Delganex be stored and disposed of?

How to Store and Dispose of Delganex?

The official storage and disposal guidelines for Delganex are structured around product integrity and security control, reflecting its classification as a controlled substance.

Storage Requirements

  • Keep the container tightly closed and store the medication in a dry place, protected from excessive moisture and heat, following the specific temperature instructions on the product label.
  • It is a mandatory regulatory requirement to keep Delganex out of the sight and reach of children at all times.

Disposal Instructions

The most secure method for disposal is through an official drug take-back program. As a controlled substance, Delganex must not be flushed down the toilet or sink. If a take-back program is unavailable, the official guidance requires mixing the medicine with an undesirable substance (such as used coffee grounds or dirt) and sealing the mixture in a container before discarding it in the household trash, following all local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Delganex found in:

A-Z Index: